Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 148.91% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.91% | -- | -- | -- | -- |
| Cost of Revenue | 4,554.55% | -- | -- | -- | -- |
| Gross Profit | -235.71% | -- | -- | -- | -- |
| SG&A Expenses | 42.75% | 40.75% | 82.61% | 51.60% | 13.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.67% | 45.70% | 63.29% | 103.33% | 45.93% |
| Operating Income | -13.19% | -44.44% | -62.64% | -102.42% | -45.42% |
| Income Before Tax | -20.77% | -42.06% | -67.76% | -109.79% | -55.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.77% | -42.06% | -67.76% | -109.79% | -55.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.77% | -42.06% | -67.76% | -109.79% | -55.92% |
| EBIT | -13.19% | -44.44% | -62.64% | -102.42% | -45.42% |
| EBITDA | -13.24% | -44.55% | -62.78% | -102.70% | -45.52% |
| EPS Basic | -15.62% | -36.23% | -64.03% | -109.14% | -55.65% |
| Normalized Basic EPS | -6.09% | -36.23% | -64.03% | -109.12% | -55.63% |
| EPS Diluted | -15.62% | -36.23% | -64.03% | -109.14% | -55.65% |
| Normalized Diluted EPS | -6.09% | -36.23% | -64.03% | -109.12% | -55.63% |
| Average Basic Shares Outstanding | 4.45% | 4.28% | 2.27% | 0.31% | 0.18% |
| Average Diluted Shares Outstanding | 4.45% | 4.28% | 2.27% | 0.31% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |